Mackay Memorial Hospital

Ascendo Biotechnology, Inc.

Yen-Ta Lu

I-Fang Tsai

Chia-Ming Chang

Chi-Kuan Chen

Wan-Ting Chen

Ling-Chiao Wu

Tsai-Yin Wei

A method for reversing immune suppression or immune exhaustion or for treating a disease associated with immune suppression includes: administering a composition to a subject in need of such treatments, wherein the composition contains a CD11b modulator that binds specifically to CD11b on a cell to inhibit PD-L1 expression. The CD11b modulator is an antibody or an antigen-binding portion thereof, or a compound as described.

Methods and antibodies for modulation of immunoresponse

A device for data management, the device is in communication with a memory and includes: a verification module configured to receive a first identity information and a first request and verify the first identity information; a search module configured to search for at least one first data stored in the memory in response to the first request if the first identity information is verified, the at least one first data being assigned a first rating point; and an evaluation module configured to receive a second rating point associated with the first identification information, retrieve the first rating point from the at least one first data and generate a third rating point in accordance with the verified first identity information, the first rating point and the second rating point and store the third rating point in the memory.

Device for data management

The present invention discloses a method for inhibiting the growth of, comprising: administering at least one selective binding agent such as an anti-CD13 antibody or a CD13 antagonist which can bind a CD13 receptor of a cell to inhibit infection of. Administration of anti-CD13 antibody can reduce an expression level of the CD13 receptor, inhibit entry ofinto monocytes, reduce survival ofin monocytes, and killeffectively.

[object Object]

Disclosed is a method for treating a symptom ofinfection in a subject, comprising administering the patient with an effective amount of (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(4-hydroxyphenyl)zetidin-2-one (EZETIMIBE). In the preferred embodiments, EZETIMIBE is capable of significantly inhibiting the survival and proliferation ofin the monocytes. The anti-tuberculous effect of EZETIMIBE is partly through stimulating CD13 leading to monocytes activation and thus bacterial killing of, and partly through depleting the intracellular nutrition necessary for the survival of. It is also proved that EZETIMIBE is capable of directly killingoutside cells.

Growing community of inventors

Taipei, Taiwan

Yen-Ta Lu